Composition for diagnosing cognitive dysfunction of companion animal by using nasal fluid

Abstract

The present disclosure relates to a composition for diagnosing cognitive dysfunction in a companion animal using a nasal fluid sample, and to a kit including the same.

1 . A composition for diagnosing cognitive dysfunction in a companion animal, comprising:
 an agent for measuring an expression level of at least one protein selected from UGT8 and BUD31, a fragment thereof, or a gene encoding the protein.   
     
     
         2 . The position of  claim 1 ,
 wherein the expression level is measured from a sample, and   wherein the sample is at least one selected from nasal fluid, saliva, blood, plasma, serum, urine, mucus, tears, sputum, cerebrospinal fluid, pleural effusion, nipple aspirate fluid, lymph, airway fluid, serous fluid, urogenital tract fluid, breast milk, lymphatic fluid, semen, cerebrospinal fluid, organ system fluid, ascites, cystic tumor fluid, and amniotic fluidef, which are isolated from a companion animal.   
     
     
         3 . The composition of  claim 2 ,
 wherein the sample is nasal fluid or saliva.   
     
     
         4 . The composition of  claim 1 ,
 wherein the expression level of the protein, the fragment thereof, or the gene can be increased compared to the expression level in a normal control group.   
     
     
         5 . The composition of  claim 1 ,
 wherein the agent for measuring the expression level of the gene includes at least one selected from primers, probes, and antisense nucleotides specifically binding to a polynucleotide encoding the protein.   
     
     
         6 . The composition of  claim 1 ,
 wherein the agent for measuring the expression level of the protein or the fragment thereof includes at least one selected from antibodies, antigen-binding fragments thereof, oligopeptides, ligands, peptide nucleic acids (PNAs), and aptamers specifically binding to the protein or the fragment thereof.   
     
     
         7 . The composition of  claim 1 ,
 wherein the cognitive dysfuntion in the companion animal includes at least one selected from mild cofnitive dysfunction, moderate cognitive dysfunction, mild Alzheimer's disease, and moderate Alzheimer's disease.   
     
     
         8 . A kit for diagnosing cognitive dysfunction in a companion animal, comprising the composition according to  claim 1 . 
     
     
         9 . A method for diagnosing cognitive dysfunction in a companion animal, comprising:
 (a) a process of selecting at least one biomarker from the group consisting of UGT8 protein, a fragment thereof, or a gene encoding the protein; and BUD31 protein, a fragment thereof, or a gene encoding the protein:   (b) a process of measuring the expression level of the selected biomarker in a sample obtained from a subject requiring diagnosis of cognitive dysfunction; and   (c) a process of comparing the measured expression level to the expression level of the selected biomarker in a normal_control group.   
     
     
         10 . The method of  claim 9 ,
 wherein the sample includes at least one selected from nasal fluid, saliva, blood, plasma, serum, urine, mucus, tears, sputum, cerebrospinal fluid, pleural effusion, nipple aspirate fluid, lymph, airway fluid, serous fluid, urogenital tract fluid, breast milk, lymphatic fluid, semen, cerebrospinal fluid, organ system fluid, ascites, cystic tumor fluid, and amniotic fluid of a companion animal.   
     
     
         11 . The method of  claim 9 ,
 wherein the process of measuring the expression level of the protein or the fragment thereof is performed by Western blotting, electrophoresis, enzyme-linked immunosorbent assay (ELISA), immunohistochemistry, protein chip, immunoprecipitation, mass spectrometry, or combinations thereof; and/or   the process of measuring the expression level of the gene is performed by RT-PCR, competitive RT-PCR, real-time RT-PCR, RNase protection assay (RPA), Northern blotting, DNA chip, or combinations thereof.   
     
     
         12 . The method according to  claim 9 ,
 wherein the method further comprises (d) a step of judging that the subject has developed cognitive dysfunction or has a high probability of developing cognitive dysfunction if the biomarker expression level of the subject is higher compared to the biomarker expression level of a normal control group after step (c).